Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Cash & Equivalents (2023 - 2026)

Camp4 Therapeutics' Cash & Equivalents history spans 3 years, with the latest figure at $109.5 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 71.02% to $109.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $109.5 million, a 71.02% increase, with the full-year FY2025 number at $109.5 million, up 71.02% from a year prior.
  • Cash & Equivalents hit $109.5 million in Q4 2025 for Camp4 Therapeutics, up from $75.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CAMP hit a ceiling of $109.5 million in Q4 2025 and a floor of $2.5 million in Q3 2024.
  • Historically, Cash & Equivalents has averaged $53.6 million across 3 years, with a median of $49.9 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: crashed 94.99% in 2024 and later soared 2878.64% in 2025.
  • Tracing CAMP's Cash & Equivalents over 3 years: stood at $38.4 million in 2023, then soared by 66.86% to $64.0 million in 2024, then surged by 71.02% to $109.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for CAMP at $109.5 million in Q4 2025, $75.3 million in Q3 2025, and $39.1 million in Q2 2025.